公开(公告)号：US20240358671A1

公开(公告)日：2024-10-31

申请号：US18687205

申请日：2022-09-07

申请人： THE TRUSTEES OF INDIANA UNIVERSITY

发明人： Chandan K. SEN ,  Sashwati ROY ,  Mithun SINHA ,  Nandini GHOSH

IPC分类号： A61K31/343 ,  A61K31/164 ,  A61P17/02 ,  A61P31/04

CPC分类号： A61K31/343 ,  A61K31/164 ,  A61P17/02 ,  A61P31/04

摘要： Compositions and methods are disclosed for treating a skin condition in a mammal in need thereof by administering to the affected tissues a therapeutically effective amount of a composition comprising a bacterial ceramidase inhibitor and/or a ceramide.

公开(公告)号：US20240350451A1

公开(公告)日：2024-10-24

申请号：US18754070

申请日：2024-06-25

申请人： Vanda Pharmaceuticals Inc.

发明人： Marlene Michelle Dressman ,  John Joseph Feeney ,  Louis William Licamele ,  Mihael H. Polymeropoulos

IPC分类号： A61K31/343 ,  A61K31/15 ,  A61K31/277 ,  A61K31/31 ,  A61K31/496 ,  A61K45/06 ,  G16H10/60 ,  G16H20/10

CPC分类号： A61K31/343 ,  A61K31/15 ,  A61K31/277 ,  A61K31/31 ,  A61K31/496 ,  A61K45/06 ,  G16H10/60 ,  G16H20/10 ,  Y02A90/10

摘要： Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g. blind patients, and to methods of measuring circadian rhythm.

公开(公告)号：US20240336583A1

公开(公告)日：2024-10-10

申请号：US18294262

申请日：2022-08-05

申请人： SHUJING BIOPHARMA CO., LTD ,  JIANGSU NHWA PHARMACEUTICAL CO., LTD

发明人： Jiaquan FENG ,  Yuanhai ZOU ,  Zehong WAN

IPC分类号： C07D305/00 ,  A61K31/05 ,  A61K31/343 ,  A61K31/665 ,  C07C37/055 ,  C07C37/14 ,  C07C37/62 ,  C07C39/17 ,  C07F9/655

CPC分类号： C07D305/00 ,  A61K31/05 ,  A61K31/343 ,  A61K31/665 ,  C07C37/055 ,  C07C37/14 ,  C07C37/62 ,  C07C39/17 ,  C07F9/65517

摘要： The present invention relates to a benzo-ring-containing derivative, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a compound as represented by general formula (Ia), and a preparation method therefor, a pharmaceutical composition containing same, and the use thereof as a GABA receptor agonist in the field of the central nervous system, specifically in inducing and maintaining anesthesia of mammals.

公开(公告)号：US20240327418A1

公开(公告)日：2024-10-03

申请号：US18293840

申请日：2022-08-01

申请人： OCEAN UNIVERSITY OF CHINA ,  QINGDAO HIGENE BIOPHARMACEUTICAL CO., LTD ,  MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO CO., LTD

发明人： Xiaoyang LI ,  Zhongren ZHOU ,  Yuqi JIANG ,  Kairui YUE ,  Wenfang XU

IPC分类号： C07D491/048 ,  A61K31/343 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/655 ,  A61P35/00 ,  A61P35/02 ,  C07C247/12 ,  C07D209/42 ,  C07D213/40 ,  C07D213/56 ,  C07D307/85 ,  C07D333/70 ,  C07D401/04 ,  C07D471/04 ,  C07D495/04

CPC分类号： C07D491/048 ,  A61K31/343 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/655 ,  A61P35/00 ,  A61P35/02 ,  C07C247/12 ,  C07D209/42 ,  C07D213/40 ,  C07D213/56 ,  C07D307/85 ,  C07D333/70 ,  C07D401/04 ,  C07D471/04 ,  C07D495/04

摘要： A compound targeting HDAC and NAD synthesis and a pharmaceutically acceptable salt, hydrate, deuterate, isomer or prodrug thereof, as well as preparation and application thereof. Specifically, a compound shown in structural general formula (I) and a pharmaceutically acceptable salt, hydrate, deuterate, isomer or prodrug thereof are provided. The compound of the structural general formula (I) is a multi-target inhibitor, targeting HDAC and NAD targets, and exhibiting significant HDAC inhibitory activity, while representative compounds exhibit certain NAD inhibitory activity.


Ring E-B-L-C (O)—(NH)r-R   (General formula I)

公开(公告)号：US20240315965A1

公开(公告)日：2024-09-26

申请号：US18546085

申请日：2022-02-10

申请人： NATURAL EXTRACTION SYSTEMS, LLC

发明人： Douglas G. METCALF

IPC分类号： A61K9/08 ,  A61K31/055 ,  A61K31/12 ,  A61K31/122 ,  A61K31/137 ,  A61K31/343 ,  A61K31/352 ,  A61K31/355 ,  A61K31/365 ,  A61K31/4741 ,  A61K31/565 ,  A61K47/02 ,  A61K47/10

CPC分类号： A61K9/08 ,  A61K31/055 ,  A61K31/12 ,  A61K31/122 ,  A61K31/137 ,  A61K31/343 ,  A61K31/352 ,  A61K31/355 ,  A61K31/365 ,  A61K31/4741 ,  A61K31/565 ,  A61K47/02 ,  A61K47/10

摘要： This patent document describes excipients that allow certain bioactive agents that exist as hydrophobic molecules to be reformulated as anions that display improved hydrophilicity, which can improve the bioavailability and pharmacokinetics of broad classes of pharmaceuticals.

公开(公告)号：US20240307511A1

公开(公告)日：2024-09-19

申请号：US18538866

申请日：2023-12-13

申请人： The Trustees of the University of Pennsylvania

发明人： Christian Hinderer ,  James M. Wilson

IPC分类号： A61K38/47 ,  A61K9/00 ,  A61K31/343 ,  A61K31/439 ,  A61K35/76 ,  A61K45/06 ,  A61K48/00 ,  A61P3/00 ,  C12N7/00 ,  C12N9/24 ,  C12N15/86

CPC分类号： A61K38/47 ,  A61K9/0019 ,  A61K31/343 ,  A61K31/439 ,  A61K35/76 ,  A61K45/06 ,  A61P3/00 ,  C12N7/00 ,  C12N9/2402 ,  C12N15/86 ,  C12Y302/01076 ,  A61K48/00 ,  A61K48/0083 ,  C12N2750/14121 ,  C12N2750/14132 ,  C12N2750/14143

摘要： A co-therapeutic regimen comprising AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDUA gene and two or more immunosuppressants is provided herein. Also provided are methods useful for treating hIDUA deficiency (MPSI) and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes.

公开(公告)号：US12083092B2

公开(公告)日：2024-09-10

申请号：US17235140

申请日：2021-04-20

申请人： Novartis AG ,  Katholieke Universiteit Leuven ,  Korea Research Institute of Chemical Technology

发明人： Johan Neyts ,  Daniel Poon ,  Keith Bruce Pfister ,  Young-Sik Jung ,  Soo Bong Han ,  Yashwardhan R. Malpani ,  Prashant Chakrasali ,  Sang-Ho Lee ,  Chong-Kyo Lee ,  Chonsaeng Kim ,  Jin Soo Shin ,  Hae Soo Kim

IPC分类号： A61K31/343 ,  A61P31/14 ,  C07D307/93

CPC分类号： A61K31/343 ,  A61P31/14 ,  C07D307/93

摘要： This disclosure provides compounds of Formula (I)






as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

公开(公告)号：US20240293441A1

公开(公告)日：2024-09-05

申请号：US18564953

申请日：2022-05-30

申请人： MATERIAS S.R.I

发明人： Domenico SALVATORE ,  Maria Angela DE STEFANO ,  Cristina LUONGO ,  Raffaele AMBROSIO ,  Tommaso PORCELLI ,  Monica DENTICE

IPC分类号： A61K31/714 ,  A61K31/12 ,  A61K31/192 ,  A61K31/198 ,  A61K31/343 ,  A61K31/352 ,  A61K31/4164 ,  A61K31/513 ,  A61K31/573 ,  A61P21/00

CPC分类号： A61K31/714 ,  A61K31/12 ,  A61K31/192 ,  A61K31/198 ,  A61K31/343 ,  A61K31/352 ,  A61K31/4164 ,  A61K31/513 ,  A61K31/573 ,  A61P21/00

摘要： Inhibitor compounds of type 2 iodothyronine deiodinase (D2) are described for use in the therapeutic treatment of muscle wasting and/or in a muscle and/or skin regenerative therapeutic method. A pharmaceutical composition comprising a type 2 iodothyronine deiodinase (D2) inhibitor compound in a pharmaceutically acceptable vehicle, as well as in combination with optional excipients, diluents and adjuvants, is also described.

公开(公告)号：US20240277654A1

公开(公告)日：2024-08-22

申请号：US18571752

申请日：2022-07-06

申请人： Mark HASLETON

发明人： Mark HASLETON

IPC分类号： A61K31/343 ,  A61P39/00

CPC分类号： A61K31/343 ,  A61P39/00

摘要： The present invention relates to a method of treating serotonin reuptake inhibitor withdrawal syndrome comprising the administration of a therapeutically effective amount of escitalopram gentisate.

公开(公告)号：US20240239752A1

公开(公告)日：2024-07-18

申请号：US18286615

申请日：2022-04-14

申请人： BioCryst Pharmaceuticals, Inc.

发明人： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Zhao Dang ,  Krishnan Raman

IPC分类号： C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

CPC分类号： C07D231/56 ,  A61K31/343 ,  A61K31/352 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/517 ,  A61K31/519 ,  C07D217/22 ,  C07D307/81 ,  C07D311/96 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

摘要： Disclosed are compounds of formulae (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity, such as Netherton Syndrome.